American Healthcare REIT 株価情報 (NYSE: AHR)

最新ニュース American Healthcare REIT (NYSE:AHR) 株価情報

American Healthcare REIT

American Healthcares

American Healthcare REIT Inc is a healthcare-focused real estate investment trust. It owns a diversified portfolio of clinical healthcare real estate properties, focusing on medical office buildings, skilled nursing facilities, senior housing, hospitals, and other healthcare-related facilities. It has four reportable business segments: integrated senior health campuses, outpatient medical, triple-net leased properties and SHOP. It generates majority of its revenue through Integrated Senior Health Campuses segment.

American Healthcare REIT, Inc. Common Stock

American Healthcare REIT Inc

AUTHENTIC HOLDINGS INC by Authentic Holdings Inc.

Authentic Holdings Inc

American Healthcare REIT Inc Ordinary Shares - Class T

Rosenblatt analyst Catharine Trebnick maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and maintains $36 price target.

News

Price Target

Analyst Ratings

FIVN

Rosenblatt Maintains Buy on Five9, Maintains $36 Price Target

<h3>Gainers</h3>
<ul>
<li>Society Pass (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPA#NASDAQ">SOPA</a>) stock rose 13.6% to $1.34 during Friday's pre-market session. The company's market cap stands at $6.6 million. </li>
<li>Brag House Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBH#NASDAQ">TBH</a>) shares moved upwards by 8.43% to $0.59. The company's market cap stands at $6.3 million. </li>
<li>Integral Ad Science Holdi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) shares increased by 7.45% to $7.64. The market value of their outstanding shares is at $1.2 billion. </li>
<li>FingerMotion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNGR#NASDAQ">FNGR</a>) shares moved upwards by 7.14% to $2.55. The market value of their outstanding shares is at $145.7 million. </li>
<li>TruGolf Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) stock increased by 6.78% to $0.31. The company's market cap stands at $13.6 million. </li>
<li>Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) shares rose 6.5% to $126.51. The company's market cap stands at $23.3 billion. The company's, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Advantage Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NASDAQ">ADV</a>) shares declined by 18.9% to $1.07 during Friday's pre-market session. The company's market cap stands at $346.0 million. </li>
<li>Emerald Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEX#NYSE">EEX</a>) stock decreased by 13.72% to $3.9. The market value of their outstanding shares is at $778.4 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Criteo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>) shares decreased by 13.27% to $28.99. The market value of their outstanding shares is at $1.5 billion. As per the press release, Q1 earnings came out today. </li>
<li>TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) stock fell 13.16% to $0.33. The market value of their outstanding shares is at $8.6 million. As per the news, the FY earnings report came out yesterday. </li>
<li>Cable One (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CABO#NYSE">CABO</a>) shares fell 12.6% to $228.98. The company's market cap stands at $1.2 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) shares decreased by 9.84% to $212.05. The market value of their outstanding shares is at $37.2 billion. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CABO

CRTO

FNGR

RDDT

SOPA

TNMG

TRUG

TTWO

12 Communication Services Stocks Moving In Friday's Pre-Market Session

The global copper market could experience a notable surplus over the next two years, as analysts anticipate rising production and weakening demand owing to<a target="_blank" href="https://www.benzinga.com/topic/trade-war" rel="noreferrer noopener"> rising international trade tensions</a>.
The International Copper Study Group (ICSG) concluded its biannual meeting in Lisbon this week, revising the projections. It now expects a <a target="_blank" href="https://icsg.org/press-releases/#" rel="noreferrer noopener">surplus of 289,000 metric tons</a> in 2025, more than double the 138,000 surplus in 2024. For 2026, it forecasts a smaller but elevated surplus of 209,000 tons owing to concerns over the economic fallout from U.S. tariffs and reduced copper usage in key global markets.
ICSG attributes the widening surplus primarily to increasing mine and smelter output. Global copper mine production is forecast to grow by 2.3% next year to 23.5 million tons, with major contributions from the ramp-up of the Ivanhoe's (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/IVPAF#OTCQX">IVPAF</a>) Kamoa-Kakula Complex in the Democratic Republic of Congo (DRC), Rio Tinto's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>) Oyu Tolgoi in Mongolia, and the new Malmyz project in Russia.
In 2026, ICSG expects mine supply to grow by a further 2.5%, bolstered by new or expanded capacity in China, Chile, and Zambia and a recovery in Indonesian output. A wave of smaller operations in countries like Iran, Brazil, Eritrea, Greece, and Angola will also contribute.
The Group anticipates refined copper output will increase by 2.9% in 2025, driven by smelting expansions in China and new capacity in India, Indonesia, and the DRC.
However, 2026 could see a contraction of 1.5% in refined output due to tighter concentrate availability, particularly for primary electrorefining. Secondary refined production, which could grow by 6.4%, will partially offset that decline, as countries invest in recycling capacity to reduce dependency on mined copper.
ICSG also downgraded its copper usage growth forecasts, citing weaker global economic prospects exacerbated by trade policy uncertainty. Refined copper usage is expected to grow by 2.4% in 2025, down from a previous forecast of 2.7%, and slow further to 1.8% in 2026.
China, the world's largest copper consumer, is forecast to see demand growth fall from 2% this year to just 0.8% next year. Other major markets, including Europe, Japan, and the United States, are expected to remain subdued, leaving broader Asia as the main driver.
While structural trends such as energy transition technology and digital infrastructure support the long-term demand for copper, the ICSG believes that current trade disruptions dampen near-term consumption.
Copper inventories on global exchanges rose by 25% in the first quarter of 2025, primarily due to a surge in holdings on the Shanghai Futures Exchange, further reinforcing the oversupply trend.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44988722/freeport-mcmoran-exceeds-q1-copper-sales-estimates-expects-lower-copper-costs-amid-tariff-concerns" target="_blank" rel="noreferrer noopener">World's Largest Copper Producer Freeport Estimates Proposed Tariffs Could Raise US Cost Of Goods Purchased By 5%</a></li>
</ul>
Photo by TimBrew via Shutterstock

Asia

Large Cap

Emerging Markets

Commodities

Global

Economics

Markets

COPX

CPER

IVPAF

JJCTF

JJMTF

JJNTF

Global Tensions To Drive Two-Year Copper Surplus, Study Group Warns

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares increased by 65.8% to $0.42 during Friday's pre-market session. The company's market cap stands at $16.7 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) shares increased by 16.81% to $2.64. The market value of their outstanding shares is at $154.6 million. The company's, Q1 earnings came out today. </li>
<li>American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) shares rose 16.15% to $7.19. The market value of their outstanding shares is at $113.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) stock moved upwards by 15.94% to $1.6. The company's market cap stands at $22.9 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares rose 12.93% to $1.22. The market value of their outstanding shares is at $41.5 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares moved upwards by 12.76% to $2.12. The market value of their outstanding shares is at $42.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) stock fell 18.8% to $0.82 during Friday's pre-market session. The company's market cap stands at $51.3 million. </li>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) stock decreased by 18.65% to $4.45. The company's market cap stands at $1.0 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares decreased by 17.45% to $0.22. The company's market cap stands at $10.0 million. </li>
<li>Tvardi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVRD#NASDAQ">TVRD</a>) shares fell 17.1% to $21.1. The company's market cap stands at $197.4 million. </li>
<li>Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) stock fell 15.76% to $9.25. The market value of their outstanding shares is at $3.8 billion. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares declined by 11.97% to $2.06. The market value of their outstanding shares is at $103.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRS

AMRN

AMWL

ARDX

ATPC

CAMP

CTSO

HCTI

MODV

PLRZ

RMTI

TVRD

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Freight Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGT#NASDAQ">FRGT</a>) stock increased by 230.0% to $3.25 during Friday's pre-market session. The market value of their outstanding shares is at $7.3 million. </li>
<li>Quad/Graphics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QUAD#NYSE">QUAD</a>) shares increased by 16.45% to $5.59. The company's market cap stands at $292.6 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Fusion Fuel Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) stock increased by 14.16% to $0.32. The market value of their outstanding shares is at $8.1 million. </li>
<li>374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) shares rose 13.87% to $0.35. The market value of their outstanding shares is at $49.8 million. </li>
<li>Babcock &amp; Wilcox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) shares increased by 8.53% to $0.5. The company's market cap stands at $49.2 million. </li>
<li>VirTra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) shares rose 7.54% to $4.99. The company's market cap stands at $56.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Hong Kong Pharma Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HKPD#NASDAQ">HKPD</a>) stock declined by 13.4% to $1.03 during Friday's pre-market session. The market value of their outstanding shares is at $11.3 million. </li>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) stock decreased by 9.32% to $0.36. The market value of their outstanding shares is at $2.5 million. </li>
<li>Odyssey Marine Explr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) shares decreased by 9.31% to $1.17. The company's market cap stands at $34.1 million. </li>
<li>Baiya International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) shares decreased by 8.1% to $4.2. The market value of their outstanding shares is at $52.5 million. </li>
<li>Resources Connection (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGP#NASDAQ">RGP</a>) shares decreased by 7.48% to $5.32. The market value of their outstanding shares is at $176.0 million. </li>
<li>Proficient Auto Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAL#NASDAQ">PAL</a>) stock fell 7.03% to $7.21. The company's market cap stands at $195.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIYA

FRGT

HKPD

HTOO

OMEX

QUAD

SCWO

SGBX

VTSI

12 Industrials Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Bit Origin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOG#NASDAQ">BTOG</a>) shares increased by 23.1% to $0.21 during Friday's pre-market session. The market value of their outstanding shares is at $12.5 million. </li>
<li>Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) shares increased by 8.3% to $106.01. The market value of their outstanding shares is at $16.1 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) shares rose 7.44% to $19.05. The company's market cap stands at $1.1 billion. </li>
<li>GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) stock moved upwards by 6.59% to $27.46. The market value of their outstanding shares is at $5.3 billion. </li>
<li>Data I/O (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAIO#NASDAQ">DAIO</a>) stock rose 6.46% to $2.47. The market value of their outstanding shares is at $22.8 million. </li>
<li>Ribbon Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) shares increased by 6.32% to $3.43. The company's market cap stands at $604.2 million. As per the press release, Q1 earnings came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) stock decreased by 15.8% to $192.86 during Friday's pre-market session. The company's market cap stands at $50.5 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Intellicheck (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDN#NASDAQ">IDN</a>) shares declined by 13.86% to $2.3. The market value of their outstanding shares is at $45.5 million. </li>
<li>inTest (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INTT#AMEX">INTT</a>) shares fell 13.19% to $5.4. The company's market cap stands at $66.8 million. As per the press release, Q1 earnings came out today. </li>
<li>Ascent Solar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTI#NASDAQ">ASTI</a>) shares fell 11.05% to $1.53. The market value of their outstanding shares is at $2.6 million. </li>
<li>Viavi Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) stock decreased by 8.83% to $9.71. The market value of their outstanding shares is at $2.1 billion. The company's, Q3 earnings came out yesterday. </li>
<li>BigBear.ai Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) stock decreased by 6.29% to $3.13. The market value of their outstanding shares is at $904.5 million. The company's, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASTI

BBAI

BTOG

DAIO

INTT

RBBN

TEAM

TWLO

VIAV

VRNT

12 Information Technology Stocks Moving In Friday's Pre-Market Session

Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced an upcoming podium presentation of findings from its Phase 1 study of PCRX-201 (enekinragene inzadenovec), a locally administered gene therapy candidate for osteoarthritis of the knee. The data will be presented at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in New Orleans on May 15. The presentation will highlight how preexisting and treatment-induced neutralizing antibodies (NAbs) impact the therapy's efficacy, safety, and redosing potential.

PCRX

Pacira BioSciences To Present Findings From Phase 1 Study Of PCRX-201 And Its Implications For Dosing Strategy In Knee Osteoarthritis At ASGCT Annual Meeting

<ul>
<li>Agreement builds on landmark licensing deal between ARS Pharma and ALK-Abelló A/S, which provided ARS Pharma with $145 million upfront and ALK with commercialization rights to neffy in Canada, United Kingdom, European Union and certain other countries outside the United States</li>
<li>New partnership expands ARS Pharma's direct promotional efforts to nearly 20,000 healthcare providers, reaching key pediatricians ahead of the back-to-school season</li>
<li>ARS Pharma expects its operating expense guidance for financial year 2025 to increase by approximately $3 million per quarter starting in the third quarter of 2025. ARS Pharma's 2025 cash flow will not be impacted.</li>
</ul>

Biotech

Health Care

Contracts

General

SPRY

ARS Pharmaceuticals Entered Into An Agreement With ALK-Abelló To Co-promote Neffy (Epinephrine Nasal Spray) For Type I Allergic Reactions, To Up To 9,000 Pediatricians, For An Upfront Of $145M

Rosenblatt analyst Steven Frankel maintains Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) with a Buy and lowers the price target from $100 to $95.

Rosenblatt Maintains Buy on Dolby Laboratories, Lowers Price Target to $95

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/02073554/Sands-ChinaJ-900x600-1.png" alt="" class="wp-image-12080" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/02073554/Sands-ChinaJ-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/02073554/Sands-ChinaJ-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/02073554/Sands-ChinaJ-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The Macao casino operator has reported a drop in quarterly profit but is banking on demand for its refurbished rooms during May's Golden Week holidays
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>Sands China's first-quarter profit fell 32% to $202 million, with adjusted property EBITDA dropping 12% to $540 million</li>
<li>After a luxury upgrade, rooms and leisure facilities at its Londoner Macao resort are now fully open for business</li>
</ul>
Investors are placing their bets on whether a leading Macao casino operator can revive its earnings after a major room revamp.
Share prices across the casino sector have been under pressure all year, amid a slowdown in Macao tourism and worries about trade tensions between China and the United States,
Against that backdrop,&nbsp;Sands&nbsp;China Ltd.&nbsp;(1928.HK), part of a US-owned casino and hotel group, has reported lower revenues and a sharp drop in profit for the first quarter. The company blamed the lackluster figures on a subdued market and renovations at its Londoner Macao resort.
The refurbished property is now ready to welcome tourists for the May holiday season, with investors keen to see whether the gamble on lavish new rooms and entertainment facilities at the British-themed resort will ultimately pay off.
Meanwhile, revenue for the first three months&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0424/2025042400029.pdf">fell</a>&nbsp;5.7% to $1.7 billion from the year-earlier quarter, while profit plunged 32% to $202 million and adjusted property EBITDA dropped 12% to $540 million. The performance was also down on the preceding quarter, when year-on-year revenue had fallen 5% and profit tumbled 17.7%. The first-quarter profit is still only about 36% of the $557 million earned in the same period of 2019, before the Covid pandemic.
Shares in Sands China eased 0.2% to HK$13.6 after the earnings release, gaining no relief from a drop of nearly 35% for the year to date. That share slide is bigger than falls at other operators: a drop of 3.2% for&nbsp;Wynn&nbsp;Macau&nbsp;(1128.HK), 14.4% for&nbsp;Galaxy Entertainment&nbsp;(0027.HK), 15.18% for&nbsp;Melco International&nbsp;(0200.HK), and 18.22% for&nbsp;SJM Holdings&nbsp;(0880.HK).&nbsp;MGM China&nbsp;(2282.HK), meanwhile, has managed a modest share rise of 1.52% this year.
Revenue fell across the Sands China Macao resorts, except for The Plaza Macao and Four Seasons Hotel Macao. The Venetian Macao, The Londoner Macao and The Parisian Macao suffered year-on-year revenue declines of 17.3%, 5.9% and 1.3% respectively. Non-gaming revenues – from rooms, food outlets, shopping and convention services – rose 7.5% at the Venetian Macao but fell 4.1% and 5.2% at the two other properties.
<h4 class="wp-block-heading">A game changer?</h4>
Aside from disruptive renovations at The Londoner, the company noted that an increase in day-trip visitors from Guangdong Province, due to easier access to visas, was not translating into higher gaming budgets or overnight stays. For example, The Venetian Macao is popular with Chinese visitors, but they are careful about the amount they spend there.
However, Sands China confirmed that all the newly renovated rooms in its luxurious Londoner Grand complex, within the Londoner resort, were now fully open to tourists as the Labor Day holidays get underway. Targeting high rollers in its main gaming rooms, the Londoner Grand offers 1,500 lavishly appointed suites and 905 standard rooms, compared with more than 4,000 rooms before the revamp. The launch of the premium suites could be a game changer for the business, although it will take time for the investment to pay off, according to CEO Grant Chum.
Although Macao tourist numbers are rising, gaming revenue is barely budging. Macao welcomed 3.06 million visitors in March, up 12.8% from a year earlier, but gambling revenue for the same period came in at 19.66 billion patacas, down 0.4% from February and up only 0.8% from the same month of 2024, according to Macao's Statistics and Census Service. Macao's Secretary for Economy and Finance, Tai Kin Ip, recently warned that fiscal revenue this year may lag forecasts, as Macao industries face tougher international competition and economic uncertainties, including the risk of an escalating trade war between the United States and China.
<h4 class="wp-block-heading">What are the odds?</h4>
In a worst-case scenario, China could cancel the gaming licenses of the three U.S.-controlled casino operators in Macao or not renew the permits when they expire in 2032, according to a report from ratings agency Fitch.
A more plausible risk, Fitch noted, is that the firms could be forced to sell their stakes in Macao casinos if relations deteriorate, although the likelihood of either scenario was rated as very low.
All three operators that are majority-owned by U.S. gaming brands are highly dependent on the Macao market. Sands China got 63% of its revenue from Macao business last year, while Wynn relied on the territory for 52% and MGM 23%. Together, the three contribute more than half of Macao's gaming revenue and gaming revenue deliver 80% of its tax revenue.
Addressing concerns, Las Vegas Sands CEO Robert Goldstein said the geopolitical risks arising from the tariff dispute would have a limited impact on Macao operations.
"We're not operating in Mainland China. We're in Macao. I think that's different," he said. "Despite current headwinds, we remain committed to long-term investments in Macao to enhance its appeal as a world-class business and leisure destination, laying a solid foundation for future growth."
The group also vowed to keep buying Sands China shares, restating a pledge to raise its controlling stake to 74.9%.
As for its price-to-earnings (P/E) ratio, Sands China trades at 14 times, higher than Wynn Macao's 9.1 times, MGM's 8.3 times, and similar to Galaxy Entertainment's 14.1 times, indicating a degree of investor confidence in its prospects. While macro challenges persist, Sands China may be poised to turn a corner, helped by policies to stimulate consumption and by its investment in opulence.

Entertainment

Equities

Gaming

Opinion

Sands China Bets On A Comeback With A Luxury Upgrade

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday.
Shares of Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/quote/xyz/earnings">worse-than-expected first-quarter financial results.</a>
Block reported quarterly earnings of 56 cents per share, which missed market estimates of 87 cents per share. Quarterly revenue came in at $5.77 billion, missing the consensus estimate of $6.2 billion.
Block shares dipped 21.9% to $45.66 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Advantage Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NASDAQ">ADV</a>) fell 18.9% to $1.07 in pre-market trading. Advantage Solutions will release financial results for the first quarter on May 12.</li>
<li>Ardelyx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) dipped 16.4% to $4.57 in pre-market trading after the company reported worse-than-expected quarterly financial results.</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) declined 16% to $192.35 in pre-market trading after the company issued fourth-quarter sales guidance below estimates.</li>
<li>LendingTree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) fell 12.9% to $47.14 in pre-market trading after the company reported worse-than-expected first-quarter sales results, issued second-quarter sales guidance below estimates, and cut its FY25 sales guidance.</li>
<li>Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) dipped 12.1% to $37.71 in pre-market trading after the company announced the FDA has extended the Prescription Drug User Fee Act action date for Aficamten.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) dropped 6.4% to $63.00 in pre-market trading after the company issued FY25 sales guidance below estimates.</li>
<li>Ingersoll Rand Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) fell 4.7% to $72.63 in pre-market trading as the company posted downbeat quarterly results and lowered its FY2025 earnings guidance.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) fell 2.9% to $207.24 in today's pre-market trading. Apple reported fiscal second-quarter revenue of $95.36 billion, beating analyst estimates of $94.53 billion. The Cupertino-based company reported second-quarter earnings of $1.65 per share, beating analyst estimates of $1.63 per share. The company&#8217;s CEO Tim Cook said that the tech giant expects a $900 million cost impact in the June quarter due to tariffs.</li>
<li>Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) fell 2.3% to $185.93 in pre-market trading. Amazon reported stronger-than-expected first-quarter financial results after market close Thursday. The company said it expects second-quarter net sales of $159 billion to $164 billion, up 7% to 11%. Analysts expect the company to have net sales of $160.91 billion in the quarter.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45133450/jim-cramer-this-consumer-cyclical-stock-is-a-one-trick-pony">Jim Cramer: This Consumer Cyclical Stock Is A &#8216;One-Trick Pony&#8217;</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Trading Ideas

AAPL

AMZN

CYTK

ROKU

TREE

Block, Atlassian, Apple, Roku, Amazon And Other Big Stocks Moving Lower In Friday's Pre-Market Session

iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.34) by 44.12 percent. This is a 30.99 percent increase over losses of $(0.71) per share from the same period last year.

Earnings

Earnings Misses

IBIO

iBio Q3 EPS $(0.49) Misses $(0.34) Estimate

AAM's 2025 Updated Financial Outlook AAM's full year 2025 financial targets are as follows: &nbsp;&nbsp;&nbsp;
<ul>
<li>AAM is targeting sales in the range of $5.65 - $5.95 billion vs. $5.8 - $6.05 billion prior.</li>
<li>AAM is targeting Adjusted EBITDA in the range of $665 - $745 million vs. $700 - $760 million prior.</li>
<li>AAM is targeting Adjusted free cash flow in the range of $165 - $215 million vs. $200 - $230 million prior; this target assumes capital spending of approximately 5% of sales.</li>
</ul>
These targets are based on the following assumptions for 2025:
<ul>
<li>North American light vehicle production of approximately 14.0 - 15.1 million units.</li>
<li>AAM's production estimates of key programs that we support.</li>
<li>AAM's outlook assumes the sale of AAM's commercial vehicle axle business in India is completed by July 1, 2025.</li>
<li>Does not reflect any costs and expenses relating to the announced combination with Dowlais, which will impact actual results. Reflects guidance for AAM on a stand-alone pre-combination basis only.</li>
<li>Substantially all incremental tariff costs are passed on to our customers.</li>
</ul>

Guidance

American Axle & Mfg Hldgs Lowers FY2025 Sales Guidance from $5.80B-$6.05B to $5.65B-$5.95B vs $5.82B Est

Throughout the last three months, 6 analysts have evaluated Universal Display (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLED#NASDAQ">OLED</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $179.67, a high estimate of $213.00, and a low estimate of $160.00. Highlighting a 9.49% decrease, the current average has fallen from the previous average price target of $198.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1746187306_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Universal Display. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Scott Searle</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$213.00</td>
<td>$207.00</td>
</tr>
<tr>
<td>Mehdi Hosseini</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$170.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$162.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$203.00</td>
<td>$234.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Universal Display. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Universal Display compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Universal Display's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Universal Display's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OLED/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Universal Display analyst ratings.</a>
<h2>Delving into Universal Display's Background</h2>
Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. The Company has one reportable business segment being OLED technologies and materials. A large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.
<h3>Unraveling the Financial Story of Universal Display</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Universal Display displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 2.51%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Universal Display's net margin excels beyond industry benchmarks, reaching 28.31%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Universal Display's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.87%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 2.52%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OLED

Demystifying Universal Display: Insights From 6 Analyst Reviews

Rosenblatt analyst Barton Crockett maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $287 to $288.

Rosenblatt Maintains Buy on Amazon.com, Raises Price Target to $288

Providing a diverse range of perspectives from bullish to bearish, 22 analysts have published ratings on Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">9</td>
<td align="right">4</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $153.14, a high estimate of $200.00, and a low estimate of $100.00. This current average reflects an increase of 3.25% from the previous average price target of $148.32. 
<img src="https://www.benzinga.com/files/images/story/2025/1746187283_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Airbnb among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$155.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Stephen Ju</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$138.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Michael Graham</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$101.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$115.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$100.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$160.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Patrick Scholes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$112.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>John Colantuoni</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$200.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Stephen Ju</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Naved Khan</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$178.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Michael Graham</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Mario Lu</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$120.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$153.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$140.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Airbnb. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Airbnb compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Airbnb's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Airbnb's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABNB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Airbnb analyst ratings.</a>
<h2>Discovering Airbnb: A Closer Look</h2>
Started in 2008, Airbnb is the world's largest online alternative accommodation travel agency; it also offers booking services for boutique hotels and experiences. Airbnb's platform offered over 8 million active accommodation listings as of Dec. 31, 2024. Listings from the company's 5 million-plus hosts are spread over almost every country in the world. In 2024, 45% of revenue was from North America, 37% from Europe, the Middle East, and Africa, 9% from Latin America, and 9% from Asia-Pacific. Transaction fees for online bookings account for all its revenue.
<h3>Breaking Down Airbnb's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Airbnb's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 11.81%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 18.59%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.46%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.14%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.27, Airbnb adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABNB

What Analysts Are Saying About Airbnb Stock

American Axle & Mfg Hldgs Q1 2025 Adj. EPS $0.09 Beats $0.02 Estimate, Sales $1.41B Miss $1.43B Estimate

Across the recent three months, 4 analysts have shared their insights on Dun &amp; Bradstreet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNB#NYSE">DNB</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $12.04, along with a high estimate of $14.00 and a low estimate of $9.15. Observing a downward trend, the current average is 12.12% lower than the prior average price target of $13.70. 
<img src="https://www.benzinga.com/files/images/story/2025/1746187269_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Dun &amp; Bradstreet Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surinder Thind</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.15</td>
<td>$11.00</td>
</tr>
<tr>
<td>Kyle Peterson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$12.80</td>
</tr>
<tr>
<td>Kyle Peterson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Dun &amp; Bradstreet Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Dun &amp; Bradstreet Holdings compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Dun &amp; Bradstreet Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Dun &amp; Bradstreet Holdings's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DNB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dun &amp; Bradstreet Holdings analyst ratings.</a>
<h2>All You Need to Know About Dun &amp; Bradstreet Holdings</h2>
Dun &amp; Bradstreet Holdings Inc is a provider of business decisioning data and analytics. The company operates in two segments: North America, which offers Finance &amp; Risk and Sales &amp; Marketing data, analytics, and business insights in the United States and Canada; and International, which offers Finance &amp; Risk and Sales &amp; Marketing data, analytics, and business insights directly in the U.K, Europe, Greater China, India and indirectly through its WWN alliances. The company generates maximum revenue from the North American region. Other services provided by the company include digital marketing, sales acceleration, and risk management among others.
<h3>Dun &amp; Bradstreet Holdings: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Dun &amp; Bradstreet Holdings displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 0.24%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 1.23%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Dun &amp; Bradstreet Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.24%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.09%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Dun &amp; Bradstreet Holdings's debt-to-equity ratio is below the industry average at 1.08, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Dun & Bradstreet Holdings Stock

5 analysts have shared their evaluations of iRhythm Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $132.4, a high estimate of $151.00, and a low estimate of $104.00. This upward trend is apparent, with the current average reflecting a 20.15% increase from the previous average price target of $110.20.
<img src="https://www.benzinga.com/files/images/story/2025/1746187257_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of iRhythm Technologies by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$151.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$124.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Nathan Treybeck</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$104.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$138.00</td>
<td>$125.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to iRhythm Technologies. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of iRhythm Technologies compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of iRhythm Technologies's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into iRhythm Technologies's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/IRTC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on iRhythm Technologies analyst ratings.</a>
<h2>Delving into iRhythm Technologies's Background</h2>
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
<h3>Understanding the Numbers: iRhythm Technologies's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: iRhythm Technologies's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 24.01%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -0.81%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): iRhythm Technologies's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.64% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.14%, the company showcases effective utilization of assets.
Debt Management: iRhythm Technologies's debt-to-equity ratio stands notably higher than the industry average, reaching 8.11. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IRTC

Deep Dive Into iRhythm Technologies Stock: Analyst Perspectives (5 Ratings)

In the preceding three months, 6 analysts have released ratings for Olaplex Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Olaplex Hldgs, presenting an average target of $1.95, a high estimate of $2.00, and a low estimate of $1.70. Marking an increase of 1.56%, the current average surpasses the previous average price target of $1.92. 
<img src="https://www.benzinga.com/files/images/story/2025/1746187245_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Olaplex Hldgs among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$2.00</td>
<td>$2.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$2.00</td>
<td>$2.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$1.70</td>
<td>$1.50</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$2.00</td>
<td>$2.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$2.00</td>
<td>$2.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$2.00</td>
<td>$2.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Olaplex Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Olaplex Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Olaplex Hldgs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Olaplex Hldgs's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OLPX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Olaplex Hldgs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Olaplex Hldgs Better</h2>
Olaplex Holdings Inc is a science-enabled, technology-driven beauty company. It offers science-backed solutions that improve hair health. It identifies the majority of consumers' relevant haircare concerns in collaboration with the community of professional hairstylists and consumers and strives to address them through its proprietary technology and innovation capabilities. It offers products through an omnichannel platform that serves professional, specialty retail, and DTC channels. The company derives its revenue through the sale of its hair care products. The company generates the majority of revenue from Professional sales channels followed by Specialty Retail and then DTC. Geographically the company generates the majority of its revenue from the International market.
<h3>Olaplex Hldgs's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining Olaplex Hldgs's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -9.82% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Olaplex Hldgs's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -8.74%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -1.0%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.5%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Olaplex Hldgs's debt-to-equity ratio is below the industry average at 0.74, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OLPX

Breaking Down Olaplex Hldgs: 6 Analysts Share Their Views

Press Releases

Real Estate

American Healthcare REIT Announces Dates for Third Quarter 2024 Earnings Release and Conference Call

American Healthcare REIT ("AHR") Announces Third Quarter 2024 Results; Increases Full Year 2024 Guidance

Dividends

American Healthcare REIT Declares Fourth Quarter 2024 Distribution

American Healthcare REIT Announces Dates for Fourth Quarter 2024 Earnings Release and Conference Call

American Healthcare REIT President & CEO, Danny Prosky, Named Healthcare Real Estate Insights™ 2024 Executive of the Year

American Healthcare REIT to Celebrate First-Year Listing Anniversary by Ringing The Opening Bell® at the New York Stock Exchange

American Healthcare REIT to Present at Citi 2025 Global Property CEO Conference

American Healthcare REIT ("AHR") Announces Fourth Quarter 2024 and Full Year 2024 Results; Issues Full Year 2025 Guidance

American Healthcare REIT Declares First Quarter 2025 Distribution

American Healthcare REIT Announces Dates for First Quarter 2025 Earnings Release and Conference Call

Comments

American Healthcare REIT

ニュース

最新ニュース American Healthcare REIT (NYSE:AHR) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル